LONA

+ Watchlist + Portfolio

LeonaBio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.83
52-Week Range: $3.53 – $14.21
Market Cap: $72.55M
P/E (TTM): —
EPS (TTM): -23.01
Dividend Yield: —

Advanced Metrics

Price/Book: 1.47
PEG Ratio: —
Return on Equity: -431.39%
Return on Assets: -74.06%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 7.01
Debt/Equity: 0.02
Total Debt: $577.00K
Free Cash Flow: $-23.75M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $23.28M

LONA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$61.46M	$93.79M	$70.68M	$17.50M
Selling, General & Admin	$32.55M	$33.30M	$26.09M	$16.68M
Operating Expenses	$88.86M	$126.94M	$96.78M	$34.18M
Operating Income	-$88.86M	-$126.94M	-$96.78M	-$34.18M
EBITDA	-$88.01M	-$125.97M	-$95.81M	-$33.21M
Pretax Income	-$95.64M	-$117.67M	-$96.94M	-$105.61M
Net Income	-$95.64M	-$117.67M	-$96.94M	-$105.61M
Diluted EPS	-25.30	-30.90	-25.20	-24.70
Diluted Shares	3.77M	3.80M	3.85M	4.28M

LONA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$95.97M	$90.58M	$48.44M	$69.28M
Receivables	$1.23M	$1.63M	$0.00	—
Current Assets	$207.53M	$154.73M	$54.84M	$89.46M
Total Assets	$258.15M	$160.25M	$58.78M	$92.15M
Current Liabilities	$21.43M	$28.84M	$13.13M	$47.50M
Total Debt	$1.91M	$1.58M	$1.22M	$803.00K
Total Liabilities	$23.02M	$30.06M	$13.94M	$64.36M
Retained Earnings	-$191.53M	-$309.21M	-$406.15M	-$511.75M
Shareholders' Equity	$235.14M	$130.19M	$44.84M	$27.79M
Working Capital	$186.10M	$125.89M	$41.71M	$41.95M

LONA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$72.47M	-$100.75M	-$97.17M	-$45.73M
Capital Expenditure	-$1.14M	-$304.00K	-$33.00K	—
Free Cash Flow	-$73.61M	-$101.06M	-$97.20M	-$45.73M
Depreciation & Amortisation	$845.00K	$969.00K	$970.00K	$972.00K
Stock-Based Compensation	$10.61M	$10.62M	$11.05M	$6.10M
Investing Cash Flow	$57.66M	$95.09M	$54.83M	-$15.89M
Financing Cash Flow	$654.00K	$493.00K	$194.00K	$82.46M
Net Change in Cash	-$14.15M	-$5.17M	-$42.15M	$20.84M

LONA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$4.30M	$3.66M	$2.83M	$6.71M	$11.26M
Selling, General & Admin	$5.23M	$3.63M	$4.05M	$3.77M	$6.88M
Operating Expenses	$9.54M	$7.29M	$6.87M	$10.48M	$18.14M
Operating Income	-$9.54M	-$7.29M	-$6.87M	-$10.48M	-$18.14M
EBITDA	-$9.29M	-$7.05M	-$6.63M	-$10.23M	-$17.91M
Pretax Income	-$9.14M	-$6.97M	-$6.61M	-$82.89M	-$32.95M
Net Income	-$9.14M	-$6.97M	-$6.61M	-$82.89M	-$32.95M
Diluted EPS	-2.34	-1.80	-1.68	—	-1.73
Diluted Shares	3.90M	3.91M	3.94M	—	19.03M

LONA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$26.42M	$19.89M	$20.87M	$69.28M	$32.83M
Current Assets	$39.85M	$32.22M	$27.02M	$89.46M	$69.20M
Total Assets	$43.51M	$35.55M	$30.03M	$92.15M	$71.59M
Current Liabilities	$5.49M	$2.98M	$2.79M	$47.50M	$6.67M
Total Debt	$1.12M	$1.02M	$912.00K	$803.00K	$691.00K
Total Liabilities	$6.18M	$3.56M	$3.25M	$64.36M	$22.29M
Retained Earnings	-$415.29M	-$422.25M	-$428.87M	-$511.75M	-$544.70M
Shareholders' Equity	$37.33M	$31.99M	$26.79M	$27.79M	$49.30M
Working Capital	$34.36M	$29.24M	$24.24M	$41.95M	$62.54M

LONA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.66M	-$7.00M	-$4.67M	-$19.40M	-$20.90M
Free Cash Flow	-$14.66M	-$7.00M	-$4.67M	-$19.40M	-$20.90M
Depreciation & Amortisation	$243.00K	$243.00K	$243.00K	$243.00K	$231.00K
Stock-Based Compensation	$1.64M	$1.60M	$1.41M	$1.46M	$662.00K
Investing Cash Flow	-$7.35M	$441.00K	$5.65M	-$14.64M	-$15.54M
Financing Cash Flow	$0.00	$24.00K	$0.00	$82.44M	$0.00
Net Change in Cash	-$22.02M	-$6.53M	$986.00K	$48.40M	-$36.44M

Market Snapshot

About

LeonaBio, Inc. is a biotechnology company focused on developing novel therapeutics for serious medical conditions. The company leverages advanced research platforms to discover and develop drug candidates. LeonaBio aims to address unmet medical needs through innovative biopharmaceutical solutions.